REGN Financial Facts

Selling, general, and administrative: 270.05M
Total revenues: 1.22B
See Full Income Statement

Other assets: 20.71M
Total liabilities: 2.34B
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/21 *Est. EPS Growth Rate +49.8% *Last Qtr.
Average EPS % Beat Rate +15.0% Revenue Growth Rate +38.3% *Last Qtr.
Average % Move 1-Wk after EPS -2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/13/12 Q411 -$0.37-$0.60 +$0.23$123M$131.04M N/A Details
7/28/11 Q211 -$0.69-$0.41 -$0.28$107.8M$121.51M N/A Details
5/3/11 Q111 -$0.49-$0.36 -$0.13$112.2M$117.02M N/A Details
11/30/-1 Q112 $0.00-$0.24 +$0.24N/A$172.62M N/A Details
7/25/12 Q212 $0.90$0.25 +$0.65$304M$255.98M N/A Details
11/5/13 Q313 $2.40$0.92 +$1.48$597M$501.93M N/A Details
8/6/13 Q213 $1.73$0.92 +$0.81$458M$470.63M N/A Details
5/8/14 Q114 $0.58$0.94 -$0.36$626M$609.04M N/A Details